These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31670756)

  • 21. Oncology Pathways-Preventing a Good Idea From Going Bad.
    Polite BN; Page RD; Nabhan C
    JAMA Oncol; 2016 Mar; 2(3):297-8. PubMed ID: 26847876
    [No Abstract]   [Full Text] [Related]  

  • 22. Current issues in oncology reimbursement.
    Bailes JS
    Oncology (Williston Park); 1995 Nov; 9(11 Suppl):185-9. PubMed ID: 8608051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An oncologist's perspective: preparation for new payment models in cancer care.
    Apte SM
    Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP169-SP172. PubMed ID: 28665674
    [No Abstract]   [Full Text] [Related]  

  • 24. Measuring the Value of New Medications and Implications for Medicare's Proposed Part B Drug Payment Model.
    Hwang TJ; LaMattina JL
    JAMA Oncol; 2016 Sep; 2(9):1125-6. PubMed ID: 27388928
    [No Abstract]   [Full Text] [Related]  

  • 25. Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs.
    Daroudi R; Mirzania M; Zendehdel K
    Int J Health Policy Manag; 2015 Oct; 5(2):99-105. PubMed ID: 26927395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost of treating cancer patients: treatments versus reimbursements.
    Goldstein MG
    Md Med; 2011; 12(4):15. PubMed ID: 22455202
    [No Abstract]   [Full Text] [Related]  

  • 27. This is a call to oncologists for action.
    Micó C; Berrocal A; Blasco A; Caballero C; Iranzo V; Lobo M; Camps C
    Clin Transl Oncol; 2018 Dec; 20(12):1493-1501. PubMed ID: 29796999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reimbursement policies constrain the practice of oncology.
    Laetz T; Silberman G
    JAMA; 1991 Dec; 266(21):2996-9. PubMed ID: 1820471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 30. Making sense of advanced payment models.
    McAneny B; Grubbs SS; Birch W; Sayam Zuckerman D
    Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP199-SP200. PubMed ID: 28665679
    [No Abstract]   [Full Text] [Related]  

  • 31. Perspectives on Cost and Value in Cancer Care.
    Saltz LB
    JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
    [No Abstract]   [Full Text] [Related]  

  • 32. Value-based contracting: creating the terms of engagement around high-cost cancer therapies.
    Dentzer S
    Am J Manag Care; 2018 Apr; 24(5 Spec No.):SP149-SP150. PubMed ID: 29905419
    [No Abstract]   [Full Text] [Related]  

  • 33. Minimalism in oncology.
    The Lancet Oncology
    Lancet Oncol; 2018 May; 19(5):579. PubMed ID: 29726372
    [No Abstract]   [Full Text] [Related]  

  • 34. Advanced APMs and the emerging role of immuno-oncology agents: balancing innovation and value.
    Seiden MV; Neubauer M; Verrilli D
    Am J Manag Care; 2017 Feb; 23(2 Spec No.):SP69-SP77. PubMed ID: 28298130
    [No Abstract]   [Full Text] [Related]  

  • 35. The new Medicare bill: far-reaching effects on cancer treatment.
    Bailes JS; Coleman T
    Clin Adv Hematol Oncol; 2004 May; 2(5):292-4. PubMed ID: 16163195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 37. Medical industry at tumor board: Three-years analysis of the open payments database and comparison of oncologic specialties.
    Baadh AS; Patel M; Patel K; Ahmed O
    J Surg Oncol; 2018 Mar; 117(4):551-557. PubMed ID: 29165809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managed care & medical oncology: the focus is on value.
    Danielson E; Demartino J; Mullen JA
    J Natl Compr Canc Netw; 2010 Sep; 8 Suppl 7():S28-37. PubMed ID: 20947721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncology payment reform to achieve real health care reform.
    McClellan MB; Thoumi AI
    J Oncol Pract; 2015 May; 11(3):223-30. PubMed ID: 25901049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncology enters the informatics era.
    Klein IM
    Am J Manag Care; 2012 Dec; 18(5 Spec No.):SP218-21. PubMed ID: 23301710
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.